Company / PP&E (Net)
Anixa Biosciences Inc PP&E (Net) History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$200.6K
FY2019
5-year range
$200.6K / $200.6K
FY2015-FY2019
Trend
+176.0%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $52,701 to $200,569 over the past 2 years.
Based on SEC 10-K filings.
$200,569 in FY2019 with a 5-year CAGR of +76.0%.
Improved from $52,701 to $200,569 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +8.6%
- 5-Year CAGR
- +76.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +76.0%, indicating consistent growth.
- In FY2019, pp&e (net) increased 176.0% year-over-year.
- Lowest pp&e (net) in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2020 | - | - |
| FY2019 | $200.6K | +176.0% |
| FY2018 | $72.7K | +37.9% |
| FY2017 | $52.7K | -66.4% |
| FY2016 | $156.6K | +260.5% |
| FY2015 | $43.5K | +265.9% |
| FY2014 | $11.9K | +15.4% |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026